ConductScience.org, home
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
API referenceFor AI assistants

Trial · NCT01263496

Participant flow54

How many started, completed or left each group, period by period.

1 to 20 of 54

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Enrolled - Long-Term Extension StudySTARTEDAlogliptin 6.25 mg Dose Group* → Alogliptin 6.25 mg Dose Group72
Enrolled - Long-Term Extension StudySTARTEDAlogliptin 12.5 mg Dose Group* → Alogliptin 12.5 mg Dose Group75
Enrolled - Long-Term Extension StudySTARTEDAlogliptin 25 mg Dose Group* → Alogliptin 25 mg Dose Group72
Enrolled - Long-Term Extension StudySTARTEDAlogliptin 50 mg Dose Group* → Alogliptin 50 mg Dose Group75
Enrolled - Long-Term Extension StudySTARTEDVoglibose 0.2 mg Dose Group* → Voglibose 0.2 mg Dose Group74
Enrolled - Long-Term Extension StudySTARTEDPlacebo Dose Group* → Alogliptin 6.25 mg Dose Group17
Enrolled - Long-Term Extension StudySTARTEDPlacebo Dose Group* → Alogliptin 12.5 mg Dose Group17
Enrolled - Long-Term Extension StudySTARTEDPlacebo Dose Group* → Alogliptin 25 mg Dose Group18
Enrolled - Long-Term Extension StudySTARTEDPlacebo Dose Group* → Alogliptin 50 mg Dose Group18
Enrolled - Long-Term Extension StudyCOMPLETEDAlogliptin 6.25 mg Dose Group* → Alogliptin 6.25 mg Dose Group71
Enrolled - Long-Term Extension StudyCOMPLETEDAlogliptin 12.5 mg Dose Group* → Alogliptin 12.5 mg Dose Group75
Enrolled - Long-Term Extension StudyCOMPLETEDAlogliptin 25 mg Dose Group* → Alogliptin 25 mg Dose Group72
Enrolled - Long-Term Extension StudyCOMPLETEDAlogliptin 50 mg Dose Group* → Alogliptin 50 mg Dose Group74
Enrolled - Long-Term Extension StudyCOMPLETEDVoglibose 0.2 mg Dose Group* → Voglibose 0.2 mg Dose Group72
Enrolled - Long-Term Extension StudyCOMPLETEDPlacebo Dose Group* → Alogliptin 6.25 mg Dose Group17
Enrolled - Long-Term Extension StudyCOMPLETEDPlacebo Dose Group* → Alogliptin 12.5 mg Dose Group17
Enrolled - Long-Term Extension StudyCOMPLETEDPlacebo Dose Group* → Alogliptin 25 mg Dose Group18
Enrolled - Long-Term Extension StudyCOMPLETEDPlacebo Dose Group* → Alogliptin 50 mg Dose Group18
Enrolled - Long-Term Extension StudyNOT COMPLETEDAlogliptin 6.25 mg Dose Group* → Alogliptin 6.25 mg Dose Group1
Enrolled - Long-Term Extension StudyNOT COMPLETEDAlogliptin 12.5 mg Dose Group* → Alogliptin 12.5 mg Dose Group0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01263496/flow

API referenceFor AI assistants